For the Inventor, By the Inventor

Enter assignee name

Berkeley, CA, United States of America

Aduro Biotech Inc.

USPTO Granted Patents = 29

CIPO Patents = 3

EPO Patents = 12

Trademarks = 5

Forward Citations = 398

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

Thomas W Dubensky, Jr (21 out of 53 patents)

Peter M Lauer (10 out of 10 patents)

Dirk G Brockstedt (10 out of 11 patents)

4. Meredith Lai Ling Leong (9 out of 9 patents)

5. David N Cook (8 out of 21 patents)

6. David Braun Kanne (7 out of 12 patents)

7. Keith Sadoon Bahjat (7 out of 14 patents)

8. Laura Hix Glickman (5 out of 15 patents)

9. Justin Skoble (5 out of 11 patents)

10. William G Hanson (5 out of 6 patents)

11. Edward Emile Lemmens (4 out of 4 patents)

12. William S Luckett, Jr (3 out of 3 patents)

13. John E Hearst (3 out of 22 patents)

14. George Edwin Katibah (2 out of 4 patents)

15. Leonard Sung (2 out of 8 patents)

29 patents: Sort by Forward Citations

1. 10738056 - Pyrazolopyrimidinone compounds and uses thereof (2020-08-11),

2. 10653774 - Compositions and methods for activating 'stimulator of interferon gene'-dependent signalling (2020-05-19),

3. 10526609 - Protein expression enhancer sequences and use thereof (2020-01-07),

4. 10449211 - Compositions and methods for activating 'stimulator of interferon gene'—dependent signalling (2019-10-22),

5. 10414789 - Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use (2019-09-17),

6. 10189873 - Compositions and methods for inhibiting 'stimulator of interferon gene'-dependent signalling (2019-01-29),

7. 10105427 - Epidermal growth factor receptor variant III-mesothelin fusions and methods of using the same (2018-10-23),

8. 9878024 - [object Object] (2018-01-30),

9. 9808516 - Immunogenic fusion proteins for the treatment of cancer (2017-11-07),

10. 9775891 - Methods and compositions for inducing an immune response to EGFRvIII (2017-10-03),

11. 9770467 - Compositions and methods for cancer immunotherapy (2017-09-26),

12. 9764013 - [object Object] (2017-09-19),

13. 9724408 - Compositions and methods for activating stimulator of interferon gene-dependent signalling (2017-08-08),

14. 9695212 - Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use (2017-07-04),

15. 9663557 - Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof (2017-05-30),

Aduro BioTech Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of immunotherapies for the treatment of various diseases, including cancer. With a strong emphasis on developing therapies based on its proprietary STING Pathway Activator technology, Aduro aims to harness the body's natural immune system to fight diseases. Through innovative research and collaborations, Aduro is committed to advancing novel treatments that can significantly impact patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

29 Patents

#20 in Berkeley, CA

#2,687 in California

#11,235 in US

#21,869 in the World

Berkeley, CA, United States of America

Aduro Biotech Inc.

Forward Citations = 398

37 inventors:

Thomas W Dubensky, Jr (21 out of 53 patents)

Peter M Lauer (10 out of 10 patents)

Dirk G Brockstedt (10 out of 11 patents)

4. Meredith Lai Ling Leong (9 out of 9 patents)

5. David N Cook (8 out of 21 patents)

Please report any incorrect information to support@idiyas.com

Loading…